Evidence map›Paper›PMID 42824609›Full record

ArticleAdvances in radiation oncology2026

Heterogeneous Radioimmunotherapy for Bulky Tumors: A Phase 1 Trial for Advanced Non-Small Cell Lung Cancer.

Ren Luo, Shanghai Liu, Jiaxi Yan, Min Yu, Renming Zhong, Kai Kang, Zhou Su, Xuanwei Zhang, Zhuoran Yao, Weigang Xiu and 20 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05615142 (Phase I Study of Low Dose Radiotherapy and Concurrent SBRT in Combination With PD-1 Inhibitors in Advanced Non-small Cell Lung Cancer), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05615142 phase1active not recruitingnot on this map

Phase I Study of Low Dose Radiotherapy and Concurrent SBRT in Combination With PD-1 Inhibitors in Advanced Non-small Cell Lung Cancer (NSCLC) .

TypeinterventionalSponsorSichuan UniversityRan2021 to 2026Enrolled9ConditionsNSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy, PD-1 InhibitorArmsLow Dose Radiotherapy, stereotactic body radiation therapy, PD-1 Inhibitors
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Ren LuoDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Shanghai LiuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jiaxi YanDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Min YuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Renming ZhongDivision of Radiation Physics, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Kai KangDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhou SuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xuanwei ZhangDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zhuoran YaoDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Weigang XiuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xiaojuan ZhouDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Feifei NaDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yan ZhangDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jiangping LiDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yang YuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yan Ying LiDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Shasha ZengDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Lin ZhouDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yong XuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Yongmei LiuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Feng PengDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jin WangDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Xianhu ZengDivision of Radiation Physics, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Bingwen ZouDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Youling GongDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Meijuan HuangDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Sen BaiDivision of Radiation Physics, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Di YanDepartment of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Jianxin XueDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
You LuDivision of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Inoperable bulky tumors remain challenging to treat with chemotherapy, radiation therapy (RT), or immune checkpoint inhibitors. We developed a novel heterogeneous RT technique with an eclipse-shaped dose distribution (EclipseRT, ERT) by embedding partial-tumor stereotactic body RT (immunogenic) within a low-dose RT (immunomodulatory) field targeting the gross tumor volume. In our previous study, we demonstrated that ERT plus anti-programmed cell death protein 1 (αPD-1) (iERT) activated the natural killer/DC/CD8⁺ T-cell axis, triggering potent antitumor immunity against bulky tumors in mouse tumor models. Here, we report a phase 1 trial to evaluate the safety and feasibility of iERT for advanced non-small cell lung cancer (NSCLC). Methods and Materials: This phase 1 trial (NCT05615142, iERT-01) employed a 3 + 3 dose-escalation design. Patients with stage IV NSCLC and bulky tumors (>5 cm) who had failed standard therapy, were ineligible for standard therapy, or declined standard therapy were enrolled. iERT was delivered in 1 to 3 fractions of 10 Gy stereotactic body RT plus 2 Gy low-dose RT with anti-programmed cell death protein 1 (αPD-1). The primary endpoint of the iERT-01 trial was safety and tolerability. Key secondary endpoints included objective response rate, progression-free survival, and overall survival. Results: A total of 9 patients with bulky NSCLC were included. The median follow-up was 22.3 months. iERT was well tolerated, with no dose-limiting toxicities observed. Overall, 7 of 9 patients (77.8%) experienced at least 1 adverse event, and 7 of 9 (77.8%) experienced treatment-related adverse events, all of which were grade 1 or 2. Moreover, it demonstrated encouraging antitumor activity, achieving an objective response rate of 55.6% (5 of 9), with a median progression-free survival of 12.6 months and a median overall survival of 26.4 months. Conclusions: iERT demonstrated favorable safety and feasibility in this phase 1 trial for advanced bulky NSCLC. Larger-cohort studies with optimized dose regimens are still warranted to further validate the novel strategy.

Identifiers

PMID42824609
PMCPMC13628653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.